News

a.z
(2023). . , 78(2), 667-673. doi: 10.22092/ari.2022.359480.2431
. "". , 78, 2, 2023, 667-673. doi: 10.22092/ari.2022.359480.2431
(2023). '', , 78(2), pp. 667-673. doi: 10.22092/ari.2022.359480.2431
. , 2023; 78(2): 667-673. doi: 10.22092/ari.2022.359480.2431

Archives of Razi Institute
Article 21, Volume 78, Issue 2, January and February 0, Pages 667-673    PDF (393.79 K)
Document Type: مقالات پژوهشی
DOI: 10.22092/ari.2022.359480.2431
Supplementary Files
References
  1. Oleg AS, Charles PV. Nelson textbook of pediatric. 2020.
  2. Burgard P, Lachmann RH, Walter J. Hyperphenylalaninaemia. In: Saudubray J-M, Baumgartner MR, Walter J, editors. Inborn Metabolic Diseases: Diagnosis and Treatment. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. p. 251-63.
  3. Perez-Duenas B, Vilaseca MA, Mas A, Lambruschini N, Artuch R, Gomez L, et al. Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin Biochem. 2004;37(12):1083-90.
  4. Belanger-Quintana A, Garcia MJ, Castro M, Desviat LR, Perez B, Mejia B, et al. Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol Genet Metab. 2005;86(1):61-6.
  5. Kareem AA, Al-Auqbi TFR, Hammoodi HZ, Shreef HR, Sallih MM. Significance of tetrahydrobiopterin in management of hyperphenylalaninemia. Iraqi J Community Med. 2020;33(1):1.
  6. Matalon R, Koch R, Michals-Matalon K, Moseley K, Surendran S, Tyring S, et al. Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med. 2004;6(1):27-32.
  7. Highland K. PKU and BH4. Advances in Phenylketonuria and Tetrahydrobiopterin. In: Blau N, editor. Advances in Phenylketonuria and Tetrahydrobiopterin: SPS Publications; 2006.
  8. Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999;135(3):375-8.
  9. Gallagher RC, Enns GM, Cowan TM, Mendelsohn B, Packman S. Aminoacidemias and Organic Acidemias. 6th ed: Swaiman's Pediatric Neurology Principles and Practice; 2018.
  10. Trefz FK, Belanger-Quintana A. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria. Drugs Today (Barc). 2010;46(8):589-600.
  11. Regier D, Greene C. Phenylalanine Hydroxylase Deficiency. In: Adam M, Ardinger H, Pagon R, editors. GeneReviews. University of Washington, Seattle: Seattle (WA); 2000.
  12. Campistol J, Gassio R, Artuch R, Vilaseca MA, Unit PKUF-u. Neurocognitive function in mild hyperphenylalaninemia. Dev Med Child Neurol. 2011;53(5):405-8.
  13. Leuret O, Barth M, Kuster A, Eyer D, de Parscau L, Odent S, et al. Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria. J Inherit Metab Dis. 2012;35(6):975-81.
  14. Muntau AC, Roschinger W, Habich M, Demmelmair H, Hoffmann B, Sommerhoff CP, et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med. 2002;347(26):2122-32.
  15. Al Riyami S, Al Maney M, Joshi SN, Bayoumi R. Detection of Inborn Errors of Metabolism using Tandem Mass Spectrometry among High-risk Omani Patients. Oman Med J. 2012;27(6):482-5.
  16. Yadav GC, Reavey PC. Aminoacidopathies: a review of 3 years experience of investigations in a Kuwait hospital. J Inherit Metab Dis. 1988;11(3):277-84.
  17. Thijeel RF. The Prevalence of Phenylketonuria and other metabolic diseases in sick Iraqi children; the importance of the newborn screening program. J Fac Med Baghdad. 2013;55(3):214-8.
  18. Opladen T, Lopez-Laso E, Cortes-Saladelafont E, Pearson TS, Sivri HS, Yildiz Y, et al. Correction to: Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020;15(1):202.
  19. Sadek AA, Hassan MH, Mohammed NA. Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years. Neuropsychiatr Dis Treat. 2018;14:2551-61.
  20. Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012;35(6):963-73.
  21. Michals-Matalon K, Bhatia G, Guttler F, Tyring SK, Matalon R. Response of phenylketonuria to tetrahydrobiopterin. J Nutr. 2007;137(6):1564-7.
  22. Zurfluh MR, Zschocke J, Lindner M, Feillet F, Chery C, Burlina A, et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat. 2008;29(1):167-75.
  23. Swoboda KJ, Walker MA. Neurotransmitter-Related disorders: Swaiman's Pediatric Neurology Principles and Practice; 2018.
  24. Vernon HJ, Koerner CB, Johnson MR, Bergner A, Hamosh A. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol Genet Metab. 2010;100(3):229-33.
  25. Cerone R, Andria G, Giovannini M, Leuzzi V, Riva E, Burlina A. Testing for tetrahydrobiopterin responsiveness in patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. Adv Ther. 2013;30(3):212-28.
  26. Christ SE, Moffitt AJ, Peck D, White DA. The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. Neuroimage Clin. 2013;3:539-47.
  27. Lindegren ML, Krishnaswami S, Reimschisel T, Fonnesbeck C, Sathe NA, McPheeters ML. A Systematic Review of BH4 (Sapropterin) for the Adjuvant Treatment of Phenylketonuria. JIMD Rep. 2013;8:109-19.
  1. Ponzone A, Guardamagna O, Spada M, Ponzone R, Sartore M, Kierat L, et al. Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes. Clin Chim Acta. 1993;216(1-2):63-71.
  2. Khatami S, Dehnabeh SR, Zeinali S, Thony B, Alaei M, Salehpour S, et al. Four Years of Diagnostic Challenges with Tetrahydrobiopterin Deficiencies in Iranian Patients. JIMD Rep. 2017;32:7-14.
Statistics
Article View: 3,036
PDF Download: 8,730


counter
Journal management system. designed by sinaweb